% This is the RIPE Database query service.
% The objects are in RPSL format.
%
% The RIPE Database is subject to Terms and Conditions.
% See https://docs.db.ripe.net/terms-conditions.html
% Information related to 'AS210418'
% Abuse contact for 'AS210418' is '[email protected]'
aut-num: AS210418
as-name: XELLIA-AS
org: ORG-XPA1-RIPE
import: from AS48374 accept ANY
export: to AS48374 announce AS210418
import: from AS3342 accept ANY
export: to AS3342 announce AS210418
admin-c: XA446-RIPE
tech-c: XA446-RIPE
status: ASSIGNED
mnt-by: RIPE-NCC-END-MNT
mnt-by: XELLIA-MNT
created: 2021-11-29T12:00:33Z
last-modified: 2021-11-29T12:00:33Z
source: RIPE
organisation: ORG-XPA1-RIPE
org-name: Xellia Pharmaceuticals ApS
country: DK
org-type: LIR
address: Dalslandsgade 11
address: 2300
address: Koebenhavn S
address: DENMARK
phone: +4532645500
e-mail: [email protected]
admin-c: XA446-RIPE
tech-c: XA446-RIPE
abuse-c: AR66700-RIPE
mnt-ref: XELLIA-MNT
mnt-by: RIPE-NCC-HM-MNT
mnt-by: XELLIA-MNT
created: 2021-11-26T07:03:45Z
last-modified: 2021-11-26T07:03:46Z
source: RIPE
role: XIO1-RIPE
address: DENMARK
address: Koebenhavn S
address: 2300
address: Dalslandsgade 11
phone: +4532645500
e-mail: [email protected]
nic-hdl: XA446-RIPE
mnt-by: XELLIA-MNT
created: 2021-11-26T07:03:45Z
last-modified: 2021-11-26T07:03:45Z
source: RIPE
% This query was served by the RIPE Database Query Service version 1.114 (SHETLAND)